2021
Gamma–Delta T‐cell Lymphomas
Foss F, Ahmed A, Xu M. Gamma–Delta T‐cell Lymphomas. 2021, 203-210. DOI: 10.1002/9781119671336.ch15.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaHepatosplenic T-cell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaFive-year overall survivalCentral nervous system prophylaxisGamma delta T cellsWorld Health Organization classificationAggressive T-cell lymphomaExtensive skin ulcerationsCurative stem cell transplantationChronic antigenic stimulationStem cell transplantationInnate immune systemMost chemotherapeutic agentsSystemic methotrexateSystem prophylaxisMedian survivalMost patientsOverall prognosisOverall survivalClinical featuresOrganization classificationRisk factors
2016
Autologous Stem Cell Mobilization in the Age of Plerixafor
Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CD34BenzylaminesCyclamsFemaleGraft SurvivalGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHeterocyclic CompoundsHumansLymphomaMaleMiddle AgedMultiple MyelomaTreatment OutcomeWorkflowConceptsStem cell mobilizationCell mobilizationPlerixafor useG-CSFAutologous stem cell transplantationAutologous stem cell mobilizationGranulocyte-colony stimulating factor (G-CSF) mobilizationDose of plerixaforLess platelet transfusionsStem cell transplantationCD34 cells/Treatment of myelomaCells/High-risk factorsEnough stem cellsStem cellsHematologic tolerancePosttransplantation therapyRelapsed lymphomaPlatelet transfusionsCell transplantationRisk factorsFactor mobilizationPatientsPlerixafor
2012
Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin Lymphoma
Kim C, Zheng T, Lan Q, Chen Y, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin Lymphoma. Cancer Epidemiology Biomarkers & Prevention 2012, 21: 866-868. PMID: 22374993, PMCID: PMC3394153, DOI: 10.1158/1055-9965.epi-12-0010.Peer-Reviewed Original ResearchConceptsRisk of NHLBody mass indexNon-Hodgkin lymphomaOxidative stress pathway genesStress pathway genesStudies of BMIPopulation-based case-control studyOxidative stressPathway single nucleotide polymorphismsOverweight/obeseCase-control studyLarger study populationIncreases oxidative stressFalse discovery rate adjustmentHistologic subtypeMass indexRisk factorsConnecticut womenNHL riskStudy populationUnderweight individualsCommon genetic variationOxidative stress genesGenetic polymorphismsSingle nucleotide polymorphisms
2002
Transformation in mycosis fungoides: The role of methotrexate
Abd-el-Baki J, Demierre MF, Li N, Foss FM. Transformation in mycosis fungoides: The role of methotrexate. Journal Of Cutaneous Medicine And Surgery 2002, 6: 109-116. PMID: 11992182, DOI: 10.1007/s10227-001-0040-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCell Transformation, NeoplasticDermatologic AgentsFemaleGenes, T-Cell Receptor gammaHumansImmunophenotypingImmunosuppressive AgentsLymphoma, Large B-Cell, DiffuseMaleMethotrexateMiddle AgedMycosis FungoidesPolymerase Chain ReactionRetrospective StudiesSkin NeoplasmsSurvival AnalysisConceptsLarge cell lymphomaRole of methotrexateMycosis fungoidesCell lymphomaDominant T-cell cloneCutaneous lymphoma databaseT cell clonesIncidence of transformationLymphoma databaseImmunosuppressive therapyMTX groupMTX exposureShort followupMulticenter studyResultsA totalRisk factorsSkin biopsiesRare disorderHigh incidencePatientsAdvanced stageMethotrexateConclusionOur resultsSignificant associationSkin specimens